These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 15942045

  • 21. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.
    Tylicki L, Renke M, Rutkowski P, Rutkowski B, Lysiak-Szydłowska W.
    Med Sci Monit; 2005 Apr; 11(4):PI31-7. PubMed ID: 15795705
    [Abstract] [Full Text] [Related]

  • 22. Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model.
    Yilmaz MI, Korkmaz A, Kaya A, Sonmez A, Caglar K, Topal T, Eyileten T, Yenicesu M, Acikel C, Oter S, Yaman H, Aktug H, Oguz Y, Vural A, Ikizler TA.
    Nephron Exp Nephrol; 2006 Apr; 104(1):e15-22. PubMed ID: 16699289
    [Abstract] [Full Text] [Related]

  • 23. Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment.
    Proesmans W, Van Dyck M, Devriendt K.
    Nephrol Dial Transplant; 2009 Apr; 24(4):1335-8. PubMed ID: 19147669
    [Abstract] [Full Text] [Related]

  • 24. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N, Zoja C, Corna D, Rottoli D, Gaspari F, Haskell L, Remuzzi G.
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [Abstract] [Full Text] [Related]

  • 25. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
    Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, Ohashi N, Nakano D, Hitomi H, Imanishi M.
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1072-80. PubMed ID: 19940106
    [Abstract] [Full Text] [Related]

  • 26. Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.
    Caletti MG, Balestracci A, Missoni M, Vezzani C.
    Pediatr Nephrol; 2013 May; 28(5):745-50. PubMed ID: 23250713
    [Abstract] [Full Text] [Related]

  • 27. [Relationship between podocyte molecule's distribution and expression, foot process morphology and proteinuria].
    Guan N, Deng JH, Ding J, Zhang JJ, Yang JY.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):139-44. PubMed ID: 15100730
    [Abstract] [Full Text] [Related]

  • 28. Nephrin and podocin loss is prevented by mycophenolate mofetil in early experimental diabetic nephropathy.
    Wu Y, Dong J, Yuan L, Liang C, Ren K, Zhang W, Fang F, Shen J.
    Cytokine; 2008 Oct; 44(1):85-91. PubMed ID: 18725182
    [Abstract] [Full Text] [Related]

  • 29. Cloning of rat homologue of podocin: expression in proteinuric states and in developing glomeruli.
    Kawachi H, Koike H, Kurihara H, Sakai T, Shimizu F.
    J Am Soc Nephrol; 2003 Jan; 14(1):46-56. PubMed ID: 12506137
    [Abstract] [Full Text] [Related]

  • 30. Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats.
    Fan Q, Xing Y, Ding J, Guan N.
    Nephron Exp Nephrol; 2009 Jan; 111(4):e92-e102. PubMed ID: 19293598
    [Abstract] [Full Text] [Related]

  • 31. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
    Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.
    Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
    [Abstract] [Full Text] [Related]

  • 32. Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
    Peters H, Border WA, Noble NA.
    Kidney Int; 2000 Apr; 57(4):1493-501. PubMed ID: 10760085
    [Abstract] [Full Text] [Related]

  • 33. Expression of nephrin, podocin, alpha-actinin, and WT1 in children with nephrotic syndrome.
    Guan N, Ding J, Zhang J, Yang J.
    Pediatr Nephrol; 2003 Nov; 18(11):1122-7. PubMed ID: 12961083
    [Abstract] [Full Text] [Related]

  • 34. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
    Xu HZ, Wang WN, Zhang YY, Cheng YL, Xu ZG.
    J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
    [Abstract] [Full Text] [Related]

  • 35. Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.
    Park HC, Choi HY, Kim BS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS.
    Kidney Blood Press Res; 2006 Dec; 29(4):216-24. PubMed ID: 16960460
    [Abstract] [Full Text] [Related]

  • 36. [Effects of multi-glycoside of Tripterygium wilfordii Hook. f. on proteinuria and expression of slit diaphragm-associated molecules in rats with anti-thy1.1 glomerulonephritis].
    Wan YG, Sun W, Wang Y.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Dec; 26(12):1094-102. PubMed ID: 17205822
    [Abstract] [Full Text] [Related]

  • 37. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.
    Agrawal V, Prasad N, Jain M, Pandey R.
    Clin Exp Nephrol; 2013 Dec; 17(6):811-8. PubMed ID: 23377573
    [Abstract] [Full Text] [Related]

  • 38. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 39. Nephrin and podocin expression around the onset of puromycin aminonucleoside nephrosis.
    Hosoyamada M, Yan K, Nishibori Y, Takiue Y, Kudo A, Kawakami H, Shibasaki T, Endou H.
    J Pharmacol Sci; 2005 Feb; 97(2):234-41. PubMed ID: 15684566
    [Abstract] [Full Text] [Related]

  • 40. Disease-causing missense mutations in NPHS2 gene alter normal nephrin trafficking to the plasma membrane.
    Nishibori Y, Liu L, Hosoyamada M, Endou H, Kudo A, Takenaka H, Higashihara E, Bessho F, Takahashi S, Kershaw D, Ruotsalainen V, Tryggvason K, Khoshnoodi J, Yan K.
    Kidney Int; 2004 Nov; 66(5):1755-65. PubMed ID: 15496146
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.